Laos Lucius version of Venetok (Venekla) product name and purchasing guide

Venetoclax is an innovative drug for the treatment of leukemia. Its active ingredient blocks the survival mechanism of cancer cells by inhibiting theBcl-2 protein that is abundantly present in leukemia cancer cells, thereby promoting the death of cancer cells and slowing down the development of the disease. LuciVenet Lao venetoclax (brand name: LuciVenet) offers an affordable treatment option for many patients.

LuciVenet is a generic drug produced by Laos Lucius Pharmaceutical Company. Its specifications are 100mg*120 tablets and the price is about 2,000 yuan. Compared with the original drug, its price is more affordable and provides many patients with an affordable treatment option.

When purchasing the Laos version of LuciVenetoclax (LuciVenet), patients can do so in the following ways:

1. Purchase abroad in person: Patients can go directly to Laos and purchase LuciVenet directly at Lucius Pharmaceutical FactoryLuciVenet. Although this method is straightforward, travel costs and time need to be taken into account.

2. Consult professional overseas medical institutions: Some institutions have direct cooperation with pharmaceutical companies and can ensure reliable sources of drugs. But be sure the agency is reputable and legally qualified.

No matter which purchase method is chosen, patients must verify the drug's trade name, manufacturer, expiration date and other information before purchasing to ensure the authenticity and safety of the drug. In addition, since the purchase and use of medicines involves personal health, patients should consult their doctors for advice before purchasing and use medicines strictly in accordance with medical instructions.

In summary, LuciVenet (Laos version of LuciVenet) provides an affordable treatment option for leukemia patients. When purchasing, patients should choose appropriate channels to ensure the authenticity and safety of the drugs, and follow the doctor's recommendations to use the drugs rationally.

References:

https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto